Investigational pharmacological agents for the treatment of ARDS
Katyayini Aribindi,Michelle Lim,Satyan Lakshminrusimha,Timothy Albertson,Katyayini AribindiMichelle LimSatyan LakshminrusimhaTimothy Albertsona Department of Internal Medicine,Division of Pulmonary,Critical Care & Sleep Medicine,U.C. Davis School of Medicine,Sacramento,CA,USAb Department of Medicine,Veterans Affairs North California Health Care System,Mather,CA,USAc Department of Pediatrics,Division of Pediatric Critical Care Medicine,U.C. Davis School of Medicine,Sacramento,CA,USAd Department of Pediatrics,Division of Neonatal-Perinatal Medicine,U.C. Davis School of Medicine,Sacramento,CA,USA
DOI: https://doi.org/10.1080/13543784.2024.2315128
2024-02-28
Expert Opinion on Investigational Drugs
Abstract:Introduction Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that results in diffuse lung inflammation with a high mortality rate. While research in COVID-related ARDS has resulted in several pharmacotherapeutic agents that have undergone successful investigation, non-COVID ARDS studies have not resulted in many widely accepted pharmacotherapeutic agents despite exhaustive research.
pharmacology & pharmacy